• 1
    Marwick C. Medical news and perspectives: alterations are ahead at the OAM. JAMA 1998; 280:15531554.MEDLINE
  • 2
    Ezzo J, Berman BM, Vickers AJ, Linde K. Complementary medicine and the Cochrane collaboration. JAMA 1998; 280:16281630.MEDLINE
  • 3
    Eisenberg DM, Kessler RC, Foster C. Unconventional medicine in the United States. N Engl J Med 1993; 328:246252.MEDLINE
  • 4
    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280:15691575.MEDLINE
  • 5
    Strader DB, Bacon BR, Lindsay KL, Hoofnagle JH, LaBrecque DR, Morgan T, Wright EC, et al. Use of complementary and alternative medicine (CAM) among patients with liver disease: survey of six hepatology outpatient clinics. Unpublished data.
  • 6
    Freemantle N, Mason J, Eccles M. Deriving treatment recommendations from evidence within randomized trials. The role and limitations of meta-analysis. Int J Technol Assess Health Care 15:304315, 1999.
  • 7
    MacIntosh AM. The differences between natural, complementary, alternative and integrative medicine. Townsend Lett July 1999.
  • 8
    Winslow LC, Krol DJ. Herbs as medicines. Arch Intern Med 1998; 158:21922199.MEDLINE
  • 9
    Bouldin AS, Smith MC, Garner DD, Szeinbach SL, Frate DA, Croom EM. Pharmacy and herbal medicine in the US. Soc Sci Med 1999; 49:279289.MEDLINE
  • 10
    McHutchison JG, Gordon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman Z, et al. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: results of a multicenter randomized controlled trial. N Eng J of Med 1998; 339:14851492.
  • 11
    Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432.MEDLINE
  • 12
    Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales G Jr, Haeussinger D, et al. Pegylated (40kDa) Interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results form a phase III, randomized, actively-controlled, multicenter trial [Abstract]. Gastroenterology 2001; 120(Suppl 1):289.
  • 13
    Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26(Suppl 1):71S77S.MEDLINE
  • 14
    Zeuzem S, Feinman V, Raseneck J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, et al. Peginteferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:16661672.MEDLINE
  • 15
    Lindsay KL, McHutchison JG, Ling MH, Albrecht JK. Response to PEG-IFN a2B (PEG-Intron) in Blacks and Hispanics is higher than with standard IFN a2B [Abstract]. Hepatology 2000; 32:347A.
  • 16
    Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med 1998; 129:10611065.MEDLINE
  • 17
    Monograph. Silybum marianum (Milk Thistle). Altern Med Rev 1999; 4:272274.MEDLINE
  • 18
    Flora K, Hahn M, Rosen H, Benner K. Milk thistle for the therapy of liver disease. Am J Gastroenterol 1998; 93:139143.MEDLINE
    Direct Link:
  • 19
    Rauen U, de Groot H. Cold-induced release of reactive oxygen species as a decisive mediator of hypothermia injury to cultured liver cells. Free Radic Biol Med 1998; 24:13161323.MEDLINE
  • 20
    Rauen U, Reuters I, Fuchs A, de Groot H. Oxygen-free radical-mediated injury to cultured rat hepatocytes during cold incubation in preservation solutions. Hepatology 1997; 26:351357.MEDLINE
  • 21
    Campos R, Gurrido A, Guerra R, Valenzuela A. Silibinin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen in rat liver. Planta Med 1989; 55:417419.MEDLINE
  • 22
    Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, Giovannini F, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995; 109:19411949.MEDLINE
  • 23
    Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23:749754.MEDLINE
  • 24
    Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26:643649.MEDLINE
  • 25
    Vogel G, Tuchweber B, Trost W. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 1984; 73:355362.MEDLINE
  • 26
    Hruby K, Cosmos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983; 2:183195.MEDLINE
  • 27
    Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9:105113.MEDLINE
  • 28
    Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, Panes J, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28:615621.MEDLINE
  • 29
    van Rossum TG, Vulto AG, De Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998; 12:199205.MEDLINE
  • 30
    Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Alternative Med Rev 1999; 4:220238.
  • 31
    Yamamoto S, Maekawa Y, Imamura H, Hisajina T. Treatment of hepatitis with antiallergic drug, Stronger Neo-Minophagen C. Clin Med Pediatr 1958; 13:73.
  • 32
    Shaikh ZA, Vu TT, Zaman K. Oxidative stress as a mechanism of chronic cadmium-induced hepatotoxicity and renal toxicity and protection by antioxidants. Toxicol Appl Pharmacol 1999; 154:256263.MEDLINE
  • 33
    Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of glycyrrhizin on NF-kappa B binding activity in CCl4-plus ethanol-induced liver cirrhosis in rats. Liver 1998; 18:180185.MEDLINE
  • 34
    Tsubota A, Kumada H, Arase Y, Chayama K, Saitoh S, Ikeda K, Kobayashi M. Suzuki Y, Murashima N. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in patients. Eur J Gastroenterol Hepatol 1999; 11:10771083.MEDLINE
  • 35
    Arase Y, Ikeda K, Murashima N. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79:14911500.
  • 36
    Reichert R. Phytotherapeutic alternatives for chronic active hepatitis. Q Rev Nat Med 1997; summer:103108.
  • 37
    Chen TSN, Chen PS. Liver in traditional Chinese medicine. J Gastroenterol Hepatol 1998; 13:437442.MEDLINE
  • 38
    Chang I-M. Liver–protective activities of aucubin derived from traditional oriental medicine. Res Comm Mol Path Pharm 1998; 102:189204.
  • 39
    Chang I-M. Antiviral activities of aucubin against hepatitis B virus replication. Phytother Res 1997; 11:189192.
  • 40
    Chang, I-M. Antiviral activity of aucubin derived from traditional Chinese herbs in HepG2, woodchucks and humans infected with hepatitis B. Complementary and Alternative Medicine in Chronic Liver Disease. Submitted abstract, p. 65.
  • 41
    Baoen W. Experimental and clinical study in inhibition and reversal of liver fibrosis with integrated Chinese and Western medicine. Complementary and Alternative Medicine in Chronic Liver Disease, Submitted abstract, p. 63.
  • 42
    Bacon BR, Li J, Britton RS, Wang B-e. Herbal Medicine 861 has direct antiproliferative effects on hepatic stellate cells. Complementary and Alternative Medicine in Chronic Liver Disease. Submitted abstract, p.56.
  • 43
    Batey RG, Bensousson A, Fan YY, Bollipo S, Hossain M. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998; 13:244247.MEDLINE
  • 44
    Tajiri H, Kozaiwa K, Ozaki Y, Harada T, Miki K, Shimuzu K, Okada S. Effect of sho-saiko-to (xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. Am J Chin Med 1991; 19:121129.MEDLINE
  • 45
    Sakaida I, Matsumara Y, Akiyama S, Hayashi K, Ishiga A, Okita A. Herbal medicine, Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998; 28:298306.MEDLINE
  • 46
    Kayano K, Sakaida I, Uchida K, Okita K. Inhibitory effect of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells. J Hepatol 1998; 29:642649.MEDLINE
  • 47
    Shimiza I, Ma Y-R, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29:149160MEDLINE
  • 48
    Oka H, Yamamoto S, Kuroki T, Harihara S, Maromo T, Kim SR, Nonna T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76:743749.MEDLINE
  • 49
    Yamashiki M, Nishimura A, Nomoto M, Suzuki W, Kosaka Y. Herbal medicine ‘Sho-saiko-to’ induces tumor necrosis factor-alpha and granulocyte colony-stimulating factor in vitro in peripheral blood mononuclear cells of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1996; 11:137142.MEDLINE
  • 50
    Li T, Tamada K, Abe K, Tada H, Onoe Y, Tatsugami K, Harada M, Kubo C, Nomoto K. The restoration of the antitumor T cell response form stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Immunopharmacology 1999; 43:1121.MEDLINE
  • 51
    Cyong JC, Ki SM, Iijima K, Kobayashi T, Furuyi M. Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chin Med 2000; 28:351360.
  • 52
    Kataria M, Singh LN. Hepatoprotective effect of Liv-52 and kumaryasava on carbon tetrachloride induced hepatic damage in rats. Indian J Exp Biol 1997; 35:655657.MEDLINE
  • 53
    Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases. A therapeutic challenge for the new millennium. Hepatology 1999; 30:10991104.MEDLINE
  • 54
    Thayagarajan SP, Subramanian S, Thirunalasundari T, Venkateswaran PS, Blumberg BS. Effect of Phyllanthus amarus on chronic carriers of hepatitis B. Lancet 1988; 2:764766.MEDLINE
  • 55
    Ott M, Thyagarajan SP, Gupta S. Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest 1997; 27:908915.MEDLINE
  • 56
    Iwu MM. African medicinal plants in the search for new drugs based on ethnobotanical leads. Ciba Foundation Symp 1994; 185:116126.
  • 57
    Iwu MM, Igboko OA, Onwuchekwa UA, Okunji CO. Evaluation of the antihepatotoxic activity of the biflavoniods of Garcinia kola seed. J Ethnopharmacol 1987; 21:27138.
  • 58
    Lewis WH, Elvin-Lewis MP. Basic quantitative and experimental research phases of future ethnobotany with reference to the medicinal plants of South America. Ciba Foundation Symp 1994; 185:6076.
  • 59
    Gran P. Medical pluralism in Arab and Egyptian history: an overview of class structures and philosophies of the main phases. Soc Sci Med 1979; 13B:339348.
  • 60
    Mousa O, Vuorela P, Kiviranta J, Wahab SA, Hiltunen R, Vuorela H. Bioactivity of certain Egyptian Ficus species. J Ethnopharmacol 1994; 41:7176.MEDLINE
  • 61
    Chawla R, Watson W, Eastin C, Lee S, Schmidt J, McClain CJ. S-adenosylmethionine (adomet) deficiency and tumor necrosis factor (TNF) in lipopolysaccharide (LPS) induced hepatic injury Am J Physiol 1998; 275:G125G129.
  • 62
    Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. J Parental Enternal Nutr 1999; 23:16.
  • 63
    Yang F, de Villiers WJS, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-α production and lethality in a murine model. J. Nutr 1998; 128:23342340.
  • 64
    Grimble RF, Grimble GK. Immunonutrition: role of sulfur amino acids, related amino acids and polyamines. Nutrition 1998; 14:605610.MEDLINE
  • 65
    McClain CJ. Alcoholic liver disease and CAM. Complementary and Alternative Medicine 1999; Submitted abstract, p59.
  • 66
    Schiano TD. Liver injury from herbs and other botanicals. Clin Liver Dis 1998; 2:607630.
  • 67
    Strader DB, Zimmerman HJ. Complementary and alternative medicine in hepatitis C. In: LiangTJ, HoofnagleJH, eds. Hepatitis C. San Diego: Academic Press, 2000:427451.
  • 68
    Palmer ME, Howland MA. Herbals and dietary supplements. In: FordM, DelaneyRJ, LingA-L, RoseCP, eds. Clinical Toxicology. Philadelphia: Saunders, 2001.
  • 69
    Ridker PM., Ohkuma S, McDermott WV, Trey C, Huxtable RJ. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88:10501054.MEDLINE
  • 70
    Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997; 157:913919.MEDLINE
  • 71
    Larrey D, vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after Germander (Teucrium chanaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117:129132.MEDLINE
  • 72
    Yahia MB, Mavier P, Metreau J-M, Zafrani ES, Fabre M, Gatineau-Saillant G, Dhumeaux D, et al. Hepatite chronique active et cirrhose induites par la germandree petit-chene. Gastroenterol Clin Biol 1993; 17:959962.MEDLINE
  • 73
    Laliberte L, Villaneuve JP. Hepatitis after the use of germander, a herbal remedy. Canadian Med Assoc J 1996; 154:16891692.
  • 74
    Anderson IB, Mullen WH, Meeker JE, Khojasteh-Bakht SC, Oishi S, Nelson SD, Blane PD. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124:726734.MEDLINE
  • 75
    Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. Brit Med J 2001; 322:139.MEDLINE
  • 76
    Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs, possible toxic components. Gut 1995; 36:146147.MEDLINE
  • 77
    Woolf GM, Petrovic LM, Royter SE, Wainwright S, Vilamil FG, Kaltov WN, Michieletti F, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994; 121:729735.MEDLINE
  • 78
    Miller LG. Herb medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158:22002211.MEDLINE
  • 79
    Bass NM. Is there any use for nontraditional or alternative therapies in patients with chronic liver disease? Current Gastroenterology Reports 1999; 1:5056.MEDLINE
  • 80
    Hoffman F, Eskinaz D. NIH Office of Alternative Medicine Conference: federal agencies explore the potential role of botanicals in US health care. J Altern Complement Med 1995; 1:303308.MEDLINE
  • 81
    Angell M, Kassirer JP. Alternative medicine—the risks of untested and unregulated remedies (Editorial). N Engl J Med 1998; 339:839841.MEDLINE